Lumbar disc herniation in osteogenesis imperfecta associated with a COL1A1 frameshift mutation: A case report and review.

Shijie Chen, Jiaqing Huang, Wugui Chen, Guangfeng Ling, Hengmei Chen, Chengshou Lin, Chengzhao Liu

Journal: Medicine 2025;104(31):e43451

PMID: 40760627

Abstract

RATIONALE

Osteogenesis imperfecta (OI) is a genetic disorder of mesenchymal hypoplasia and collagen defects. Whether abnormal type I collagen predisposes OI patients to multilevel lumbar disc herniation remains unclear.

PATIENT CONCERNS

An 18-year-old male with childhood-diagnosed type I OI (fragility fractures, blue sclera, dentinogenesis imperfecta, severe osteoporosis) developed progressive low-back pain and bilateral radiculopathy.

DIAGNOSES

Magnetic resonance imaging revealed multilevel lumbar disc herniation with relatively mild nucleus pulposus degeneration. Whole-exome sequencing identified a de novo COL1A1 frameshift mutation (c.441delC, p.Gly148Aspfs*117) resulting in premature termination. AlphaFold 3 modelling predicted markedly truncated and structurally altered chains.

INTERVENTIONS

Minimally invasive microdiscectomy, systemic antiosteoporosis therapy (bisphosphonate, calcium/vitamin D), and staged functional rehabilitation were implemented.

OUTCOMES

Neurological symptoms improved postoperatively during >2 years of follow-up, while a new femoral fracture occurred in 2023.

LESSONS

OI patients with COL1A1/COL1A2 mutations may have heightened susceptibility to disc herniation despite modest disc degeneration. Integrating magnetic resonance imaging, genetic testing, and artificial intelligence structural modelling refines diagnosis and pathophysiological understanding. Multidisciplinary management combining targeted surgery, antiosteoporosis therapy, and rehabilitation optimizes long-term outcomes.

Copyright © 2025 the Author(s). Published by Wolters Kluwer Health, Inc.

Address: Department of Spinal Surgery, Fujian Medical University Affiliated Mindong Hospital, Ningde, Fujian Province, China.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.